by Kenny Dolgin, Healthcare Analyst, Guidepoint Data
Guidepoint Data is excited to announce that we have expanded Guidepoint Qsight’s data product offering to include models for three new companies: Merit Medical (“MMSI”), CONMED (“CNMD”), and SI-BONE (“SIBN”).
For Merit Medical, Guidepoint Qsight’s data and projection methodology has been more accurate than consensus each of the past four quarters. Most notably, prior to MMSI’s Q4 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to come in above sell-side consensus estimates. On February 26th, MMSI’s Q4 2018 reported U.S. sales outperformed Street expectations, sending the stock price up +7% at market open the next day.
For CONMED, Guidepoint Qsight’s data and projection methodology has been more accurate than consensus each of the past 4 quarters. Most notably, prior to CNMD’s Q4 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to come in above sell-side consensus estimates. On January 22nd, CNMD’s Q4 2018 reported U.S. sales outperformed Street expectations, sending the stock price up +5% at market open the next day.
QSIGHT OVERVIEW
Prior to SI-BONE’s Q4 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to come in above sell-side consensus estimates. On March 7th, SIBN’s Q4 2018 reported U.S. sales outperformed Street expectations, sending the stock price up +5% at the high the next day.
QSIGHT OVERVIEW
Guidepoint Qsight’s U.S. hospital purchasing data captures medical products and devices purchased by over 1,500 hospitals. The monthly data is updated on a weekly basis which allows for near real-time capture of actual spend, market growth, pricing dynamics and market share shifts among manufacturers. Qsight utilizes the data and provides revenue projections for the upcoming quarter via easy-to-use Excel models. Below is a list of Qsight’s product models currently offered:
Edwards Lifesciences (EW), Abiomed (ABMD), Penumbra (PEN), Intersect ENT (XENT), Wright Medical (WMGI), Zimmer Biomet (ZBH), Intuitive Surgical (ISRG), Smith & Nephew (SNN), Cardiovascular Systems (CSII), Atricure (ATRC), Boston Scientific (BSX), Stryker (SYK), (NEW) Merit Medical (MMSI), (NEW) CONMED (CNMD), (NEW) SI-BONE (SIBN)
Guidepoint is not a registered investment adviser and cannot transact business as an investment adviser or give investment advice. The information, analyses, forecasts, metrics, samples, estimated figures, trends, charts, tables, graphs, and projections contained herein or in any Guidepoint Data Product do not represent, contain or constitute investment advice and are not intended as an offer to sell or solicitation of an offer to buy any security, or as a recommendation to buy or sell any security and should not be relied upon as the basis for any transactions in securities.